Capital Performance Advisors LLP Verve Therapeutics, Inc. Transaction History
Capital Performance Advisors LLP
- $325 Million
- Q3 2024
A detailed history of Capital Performance Advisors LLP transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Capital Performance Advisors LLP holds 141 shares of VERV stock, worth $836. This represents 0.0% of its overall portfolio holdings.
Number of Shares
141Holding current value
$836% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VERV
# of Institutions
176Shares Held
71.8MCall Options Held
115KPut Options Held
144K-
Alphabet Inc. Mountain View, CA12.3MShares$73.2 Million3.79% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$39.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$31.2 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.53MShares$26.9 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.87MShares$23 Million0.01% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $355M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...